ENXTPA:IPN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Ipsen S.A. operates as a biopharmaceutical company worldwide.


Snowflake Analysis

Reasonable growth potential second-rate dividend payer.


Similar Companies

Share Price & News

How has Ipsen's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IPN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

5.1%

IPN

3.2%

FR Pharmaceuticals

6.4%

FR Market


1 Year Return

-35.1%

IPN

15.2%

FR Pharmaceuticals

-4.4%

FR Market

Return vs Industry: IPN underperformed the French Pharmaceuticals industry which returned 15.5% over the past year.

Return vs Market: IPN underperformed the French Market which returned -6.6% over the past year.


Shareholder returns

IPNIndustryMarket
7 Day5.1%3.2%6.4%
30 Day9.3%1.0%13.0%
90 Day23.0%0.1%-5.7%
1 Year-34.2%-35.1%19.1%15.2%-2.7%-4.4%
3 Year-38.1%-40.4%11.1%-0.9%8.2%-0.5%
5 Year52.5%44.7%21.0%0.3%27.0%10.8%

Price Volatility Vs. Market

How volatile is Ipsen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Ipsen undervalued compared to its fair value and its price relative to the market?

39.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: IPN (€71.6) is trading below our estimate of fair value (€118.34)

Significantly Below Fair Value: IPN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: IPN is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: IPN is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IPN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IPN is overvalued based on its PB Ratio (3.4x) compared to the FR Pharmaceuticals industry average (2.5x).


Next Steps

Future Growth

How is Ipsen forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

27.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IPN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.6%).

Earnings vs Market: IPN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: IPN's is expected to become profitable in the next 3 years.

Revenue vs Market: IPN's revenue (1.5% per year) is forecast to grow slower than the French market (3.9% per year).

High Growth Revenue: IPN's revenue (1.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IPN's Return on Equity is forecast to be high in 3 years time (20.5%)


Next Steps

Past Performance

How has Ipsen performed over the past 5 years?

10.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IPN is currently unprofitable.

Growing Profit Margin: IPN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IPN is unprofitable, but has reduced losses over the past 5 years at a rate of 10% per year.

Accelerating Growth: Unable to compare IPN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IPN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5.5%).


Return on Equity

High ROE: IPN has a negative Return on Equity (-3.1%), as it is currently unprofitable.


Next Steps

Financial Health

How is Ipsen's financial position?


Financial Position Analysis

Short Term Liabilities: IPN's short term assets (€1.3B) do not cover its short term liabilities (€1.5B).

Long Term Liabilities: IPN's short term assets (€1.3B) exceed its long term liabilities (€1.1B).


Debt to Equity History and Analysis

Debt Level: IPN's debt to equity ratio (74.7%) is considered high.

Reducing Debt: IPN's debt to equity ratio has increased from 2.4% to 74.7% over the past 5 years.

Debt Coverage: IPN's debt is well covered by operating cash flow (47.9%).

Interest Coverage: IPN is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet


Next Steps

Dividend

What is Ipsen's current dividend yield, its reliability and sustainability?

1.40%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: IPN's dividend (1.4%) isn’t notable compared to the bottom 25% of dividend payers in the French market (1.71%).

High Dividend: IPN's dividend (1.4%) is low compared to the top 25% of dividend payers in the French market (5.03%).


Stability and Growth of Payments

Stable Dividend: IPN's dividends per share have been stable in the past 10 years.

Growing Dividend: IPN's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: IPN is paying a dividend but the company is unprofitable.


Future Payout to Shareholders

Future Dividend Coverage: IPN's dividends in 3 years are forecast to be thoroughly covered by earnings (14.5% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Aymeric Le Chatelier (50yo)

0.42

Tenure

Mr. Aymeric Le Chatelier has been an Executive Vice President and Chief Financial Officer at Ipsen S.A. since November 3, 2014 and serves as its Chief Executive Officer and served as its Interim Chief Exe ...


Leadership Team

NamePositionTenureCompensationOwnership
Aymeric Le Chatelier
CEO, CFO & Executive VP0.42yrno datano data
Aidan Murphy
Executive Vice President of Technical Operations2.42yrsno datano data
Eugenia Litz
Vice President of Investor Relations4yrsno datano data
François Garnier
Executive VP & General Counsel5.5yrsno datano data
Christian Marcoux
Senior Vice-President of Global Communications1.5yrsno datano data
Régis Mulot
Executive VP & Chief Human Resources Officer2.25yrsno datano data
Stephan Gagne
Head of New Tokyo Office9.33yrsno datano data
Dominique Laymand
Executive VP of Ethics & Social Responsibility Officer1.42yrsno datano data
Benoît Hennion
Executive VP & President of Consumer Healthcare3.25yrsno datano data
Dominique Bery
Executive Vice President of Strategy & Transformation3.17yrsno datano data

2.8yrs

Average Tenure

53yo

Average Age

Experienced Management: IPN's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Marc M. de Garidel
Non-Executive Chairman9.58yrs€600.00k0.17% 10.1m
Margaret Liu
Independent Director3yrs€120.00k0.00083% 49.4k
Michèle Ollier
Independent Director5.08yrs€67.36k0.00060% 35.7k
Antoine Flochel
Vice Chairman12yrs€168.85k0.0036% 214.6k
Henri Beaufour
Director14.83yrs€33.04k26.27% 1.6b
Anne Beaufour
Director14.83yrs€48.32k26.27% 1.6b
Christian de la Tour
Chairman of Ipsen UK11.25yrsno datano data
Carol Xueref
Director8yrs€122.84k0.00060% 35.7k
Philippe Bonhomme
Director8.42yrs€121.30k0.00060% 35.7k
Carol Stuckley
Independent Director3yrs€135.00k0.00060% 35.7k

9.0yrs

Average Tenure

60yo

Average Age

Experienced Board: IPN's board of directors are considered experienced (9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Ipsen S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ipsen S.A.
  • Ticker: IPN
  • Exchange: ENXTPA
  • Founded: 1929
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €5.946b
  • Shares outstanding: 83.04m
  • Website: https://www.ipsen.com

Number of Employees


Location

  • Ipsen S.A.
  • 65, quai Georges Gorse
  • Cedex
  • Boulogne-Billancourt
  • Ile-de-France
  • 92650
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IPNENXTPA (Euronext Paris)YesOrdinary SharesFREURDec 2005
I7GDB (Deutsche Boerse AG)YesOrdinary SharesDEEURDec 2005
0MH6LSE (London Stock Exchange)YesOrdinary SharesGBEURDec 2005
IPSE.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDDec 2005
IPNPBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURDec 2005
IPN NBMV (Bolsa Mexicana de Valores)YesOrdinary SharesMXMXNDec 2005
IPSE.YOTCPK (Pink Sheets LLC)SPON ADRUSUSDAug 2007

Biography

Ipsen S.A. operates as a biopharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in the areas of oncology, neuroscience, pituitary pathologies and growth disorders, gastrointestinal disorders, neurodegenerative pathologies, and rheumatology. Its products include Somatuline for neuroendocrine tumors and acromegaly; Cabometyx to treat renal cell and second-line hepatocellular carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl to treat advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; and Dysport for motor muscular disorders and medical aesthetics. The company also provides NutropinAq to treat growth failure in children due to growth hormone deficiency, turner syndrome, or chronic renal failure, as well as GH deficiency in adults; and Increlex for long-term treatment of growth failure in children and adolescents. In addition, it offers Smecta for the treatment of chronic and acute diarrhea, and pain linked to oesogastroduodenal conditions and colic; Forlax for constipation; and Fortrans/Eziclen for intestinal cleaning; Etiasa for inflammatory bowel diseases; and Tanakan to treat mild cognitive impairment related to age, pathophysiological deficiencies, vertigo, retinal deficits, acute or chronic hearing impairment, and tinnitus. Further, the company provides Adenuric for chronic hyperuricaemia; Prontalgine, an analgesic to treat moderate to severe pain; Buscopan, an antispasmodic; Suppositoria Glycerini, a laxative; and Mucothiol and Mucodyne, which are expectorants for cough and flu. The company has a strategic agreement with Arix Bioscience plc; and a global licensing and joint development agreement with The University of Texas MD Anderson Cancer Center. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/03 21:28
End of Day Share Price2020/06/03 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.